Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials

By sjmartinez • February 8, 2025

Merola JF, Ferris LK, Sobell JM, Sofen H, Osborne J, Vaile J, Jou YM, Daamen C, Scotto J, Scharnitz T, Lebwohl M. Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials. Dermatol Ther (Heidelb). 2025 Feb 7. doi: 10.1007/s13555-025-01337-x. Epub ahead of print. PMID: 39918727.

Tags: Adverse event, Clinical Trial, Dermatology, deucravacitinib, long-term, Olive View DoM, psoriasis, Publications, real-world, registry, safety, TYK2, tyrosine kinase 2

Cutaneous Larva Migrans

Truong A, Martin S. Cutaneous Larva Migrans. N Engl J Med. 2025 Feb 20;392(8):e22. doi: 10.1056/NEJMicm2414639. PMID: 39970399.

Tezepelumab for the Treatment of Chronic Spontaneous Urticaria: Results of the Phase 2b INCEPTION Study

McLaren J, Chon Y, Gorski KS, Bernstein JA, Corren J, Hayama K, Jain V, Lima H, Sofen H, Ponnarambil S, Molfino NA, Maurer M. Tezepelumab[...]

Genetic and anatomical determinants of olfaction in dogs and wild canids

Mouton A, Bird D, Li G, Craven BA, Levine JM, Morselli M, Pellegrini M, Van Valkenburgh B, Wayne RK, Murphy WJ. Genetic and anatomical determinants[...]